Arbutus Biopharma Corporation

As of June 30, 2026, Arbutus Biopharma Corporation carries a market capitalization of 826.90M, placing it among publicly traded companies globally. Its enterprise value stands at 746.28M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Arbutus Biopharma Corporation's next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Arbutus Biopharma Corporation has 197.63M shares outstanding.

As of June 30, 2026, Arbutus Biopharma Corporation trades at a trailing price-to-earnings ratio of 6.06. The price-to-sales ratio is 5.10, and the price-to-book ratio stands at 3.65.

As of June 30, 2026, Arbutus Biopharma Corporation trades at an EV/EBITDA multiple of 5.72 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.69 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 5.72 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 746.28M versus a market cap of 826.90M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Arbutus Biopharma Corporation maintains a current ratio of 81.42, meaning it holds 81.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.20, indicating conservative leverage, while an interest coverage ratio of 1,961.04 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Arbutus Biopharma Corporation posted a return on equity (ROE) of 89.58, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 86.80 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 81.13, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 89.21, useful for judging operating efficiency across full business cycles. The company generates approximately 6.30M in revenue per employee across its workforce of 25.25, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Arbutus Biopharma Corporation's stock has declined approximately 1.26% over the past 52 weeks. The 50-day moving average sits at 4.18, while the 200-day moving average is 3.90.

Over the twelve months ended June 30, 2026, Arbutus Biopharma Corporation generated 159.06M in revenue and converted that into 133.97M in net income, yielding earnings per share of 0.69. EBITDA reached 130.45M, while operating income came in at 129.04M.

As of June 30, 2026, Arbutus Biopharma Corporation holds 81.07M in cash and equivalents against 449,904.20 in total debt, resulting in a net debt position of -16.78M. Total book value stands at 226.47M, with working capital of 236.79M providing operational flexibility.

Arbutus Biopharma Corporation produced -21.55M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -21.55M - equivalent to -0.11 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of 81.13 and net profit margin of 84.23 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -2.65: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.83, meaning Arbutus Biopharma Corporation raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Arbutus Biopharma Corporation has an Altman Z-Score of 34.48, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.